Weight-loss drug developer Metsera is targeting an up to $1.78 billion valuation in its initial public offering, the ARCH Venture Partners-backed biotech company said on Monday. New York City-based ...

ARCH is one of the leading U.S. producers of high-quality metallurgical coal (“met coal”). This is the kind of coal used for ...

(Reuters) -Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial public offering in the United States. The South San Francisco, ...

Brendan Wallace has a lot on his mind lately. Wallace is the co-founder of Fifth Wall Ventures, a nine-year-old proptech ...

If you have a tip about tech, startups or the venture industry, contact Troy Wolverton at [email protected] or via ...

The deal would value the firm at about $2 billion and mark the latest push by private equity into the industry.

After a frenetic first couple of weeks as far as big rounds go, this week was quieter than a library. Only one round of more ...

Reports suggest that markets are projected to bounce back, making 2025 one of the strongest years in recent memory for ...

Discover how shrinking markets are forcing VCs to adapt. Will they stick to local ecosystems or compete globally to retain ...

The world’s richest man has been passed up for his arch-nemesis in Trump’s flagship tech project. How the tables turn ...

On Thursday, Madrona announced a $770 million raise to launch what it is calling Fund X and Acceleration Fund IV. Fund X will support about 30 companies at the pre-seed, seed or Series A stage, ...

The top tech companies Tuesday announced that they will create a new company, called Stargate, to grow artificial ...